Home > Browse Reports > Biotechnology > RNA Interference Markets

Report Description

RNA Interference Markets
Publication Date: 01-DEC-08
Pages: 147
Study: TMRRNAI
Format/Price: PDF document / $3,400.00
   


Description:



View Sample PDF


Since its discovery, the naturally occurring RNA (ribonucleic acid) interference effect has been acclaimed as the most exciting technical breakthrough in biological research in the last decade. Some industry analysts predict that RNA interference (RNAi) may even surpass PCR as a top technology. RNAi allows scientists to silence the expression or effect of a gene under study. This is known as gene knockdown. This field has rapidly emerged as a fast-growing new market. The purpose of this TriMark Publications report is to review the market for RNAi testing equipment and supplies. RNAi is a mechanism in molecular biology where the presence of certain fragments of double-stranded RNA (dsRNA) interferes with the expression of a particular gene which shares a similar sequence with the dsRNA. This study defines the dollar volume of sales, both worldwide and in the U.S., and analyzes the factors that influence market size and growth for RNAi testing. The main objectives of this study are to: 1) understand the different sectors of RNAi testing market and to look at a description of the instruments, reagents and supplies marketed by major companies in each segment; 2) obtain a complete understanding of the individual RNAi-testing platforms-from basic principles to clinical applications; 3) discover feasible market opportunities by identifying high-growth applications in different analytical diagnostic areas, with a focus on the biggest and expanding markets; 4) focus on global industry developments and trends through an in-depth analysis of the major world markets for RNAi measurement technology, including growth forecasts; and 5) present market figures related to the current value of RNAi testing, market projections, market share, key players and sector growth rates.





Table of Contents:

  1. 1 Overview 6
  2. 1.1 Objectives 6
  3. 1.2 Scope 6
  4. 1.3 Methodology 8
  5. 1.4 Executive Summary 9
  6. 2 RNA Interference (RNAi) 12
  7. 2.1 Introduction 12
  8. 2.2 Overview of RNA Interference 12
  9. 2.2.1 Classes of Endogenous Small RNAs: siRNA, rasiRNA and miRNA 13
  10. 2.2.2 Mechanism of RNAi In Vivo 14
  11. 2.3 Glossary 17
  12. 2.4 What Areas of Research Does RNAi Impact? 18
  13. 2.4.1 RNAi Technology in Life Sciences Research, Drug Discovery and Development 19
  14. 2.4.2 RNAi Technology in Agriculture 25
  15. 3 Technology Trends in RNAi Space 28
  16. 3.1 Overview 28
  17. 3.2 End-User Segmentation 28
  18. 3.3 Technologies for Inducing RNAi 29
  19. 3.3.1 Methods for Detecting Gene Silencing 30
  20. 3.3.2 Comparison of Strategies for Target Validation 31
  21. 3.3.3 Libraries of siRNAs/shRNAs to Knock Down Genes En Masse 31
  22. 3.4 miRNA-Based RNAi: The Leading Edge of RNAi Space 37
  23. 3.4.1 Biological Function of miRNAs 38
  24. 3.4.2 Role of miRNAs in Disease 39
  25. 3.4.3 miRNA-based Diagnostics 43
  26. 3.4.4 miRNA-based Therapeutics 45
  27. 3.5 Market Shifts in RNAi Space: Where Is It Headed? 46
  28. 3.5.1 Intellectual Property and Patent Issues 47
  29. 3.5.2 Patents Covering the Molecular Characteristics of the RNAi Agent 47
  30. 3.5.3 Funding in RNAi Space: Grants, Venture Capital and IPOs 49
  31. 3.5.4 Partnerships, Alliances, Mergers and Acquisitions 50
  32. 3.6 SWOT Analysis of Technologies and Vendors in RNAi Space 52
  33. 4 RNAi Market Analysis 55
  34. 4.1 Overview 55
  35. 4.2 Market Data Collection and Respondent Pool 55
  36. 4.2.1 Respondent Pool Characteristics 55
  37. 4.3 RNAi Technologies / Products in Research Applications 57
  38. 4.4 RNAi Technologies/Products: Market Shares (Quantitative) 58
  39. 4.5 Quantitative Metrics of RNAi Usage: Market Opportunity and Growth 61
  40. 4.5.1 Growth of Various Segments in RNAi Space 63
  41. 4.5.2 Product Formats and Representation in RNAi Marketplace 64
  42. 4.6 RNAi Marketplace: Challenges, Unmet Needs and Drivers 70
  43. 4.6.1 Unmet Needs in RNAi Space 71
  44. 4.6.2 RNAi Market: Qualitative Growth Drivers 73
  45. 5 The RNAi Landscape 74
  46. 5.1 Overview 74
  47. 5.2 Market Segmentation of RNAi and Segment Characteristics 74
  48. 5.3 Quantitative Market Opportunities in RNAi Space 76
  49. 5.3.1 Opportunities in miRNA Space 76
  50. 5.3.2 Opportunities in siRNA/shRNA Space 78
  51. 5.4 RNAi Product Offerings and Associated Business Models 79
  52. 5.5 Challenges for RNAi Therapeutic Development 81
  53. 6 RNAi-Based Therapeutics: The Emerging Industry Landscape 83
  54. 6.1 Factors Contributing to the Success of RNAi Therapeutics 83
  55. 6.2 Advantages and Disadvantages of siRNA-based Drugs 84
  56. 6.3 Opportunities and Challenges with RNAi-based Therapeutics 84
  57. 6.4 The Gene Therapy Precedent 85
  58. 6.5 The Antisense Precedent 86
  59. 6.6 Interferon Response 86
  60. 6.7 Delivery of RNAi-based Therapeutics 87
  61. 6.8 Off-Target Effects 89
  62. 6.9 Overwhelming the Endogenous RNAi System-Affecting the microRNA Pathway 89
  63. 6.10 RNAi-based Therapeutics 89
  64. 6.10.1 Cancer 90
  65. 6.10.2 Cardiac Disease 92
  66. 6.10.3 Immunologic Disease 93
  67. 6.10.4 Infectious Disease 93
  68. 6.10.5 Inflammation 96
  69. 6.10.6 Lifestyle Therapeutics 96
  70. 6.10.7 Metabolic Disease 96
  71. 6.10.8 Neurologic Disease 97
  72. 6.10.9 Ophthalmic Disease 97
  73. 6.10.10 Renal Disease 99
  74. 6.10.11 Respiratory Disease 99
  75. 7 Company Profiles-U.S. 100
  76. 7.1 Alfacell Corporation 101
  77. 7.2 Allele Biotechnology and Pharmaceuticals, Inc. 101
  78. 7.3 Alnylam Pharmaceuticals 101
  79. 7.4 Ambion 103
  80. 7.5 Asuragen, Inc. 104
  81. 7.6 Avalon Pharmaceuticals, Inc. 104
  82. 7.7 B-Bridge International, Inc. 105
  83. 7.8 Bio-Rad Laboratories 105
  84. 7.9 Calando Pharmaceuticals, Inc. 106
  85. 7.10 Cepheid 106
  86. 7.11 Cequent 106
  87. 7.12 Clontech Laboratories, Inc. 107
  88. 7.13 CombiMatrix Corporation 107
  89. 7.14 Cyntellect, Inc. 107
  90. 7.15 CytRx Corp. 108
  91. 7.16 Dharmacon 109
  92. 7.17 Dicerna 109
  93. 7.18 Galenea Corporation 109
  94. 7.19 GeneCopoeia, Inc. 110
  95. 7.20 GeneThera, Inc. 110
  96. 7.21 Genlantis 110
  97. 7.22 GenoSensor 110
  98. 7.23 GRL, Inc. 111
  99. 7.24 IDT 111
  100. 7.25 Imgenex Corporation 111
  101. 7.26 Ingenuity Systems 112
  102. 7.27 Intradigm Corporation 112
  103. 7.28 Invitrogen 112
  104. 7.29 InvivoGen 113
  105. 7.30 Isis Pharmaceuticals, LLC 113
  106. 7.31 LC Sciences 114
  107. 7.32 Lentigen Corporation 115
  108. 7.33 MDRNA 115
  109. 7.34 Merck & Co., Inc. 115
  110. 7.35 Mirus Bio Corporation (Acquired by Roche) 115
  111. 7.36 Monsanto 116
  112. 7.37 Nastech Pharmaceutical Company, Inc. 116
  113. 7.38 New England BioLabs 117
  114. 7.39 Nucleonics, Inc. 117
  115. 7.40 Open Biosystems, Inc. 118
  116. 7.41 OPKO Health, Inc. 119
  117. 7.42 OriGene 119
  118. 7.43 Panomics, Inc. 119
  119. 7.44 PhaseRx 120
  120. 7.45 Promega Corp. 120
  121. 7.46 Quark Pharmaceuticals, Inc. 120
  122. 7.47 RXi Pharmaceuticals Corporation 121
  123. 7.48 Senetek PLC 121
  124. 7.49 Sigma-Aldrich 122
  125. 7.50 Sirna Therapeutics 122
  126. 7.51 Sirnaomics, Inc. 123
  127. 7.52 SomaGenics, Inc. 124
  128. 7.53 System Biosciences 124
  129. 7.54 Tacere Therapeutics 125
  130. 7.55 Targeted Genetics Corporation 125
  131. 7.56 Third Wave Technologies 126
  132. 7.57 Traversa 126
  133. 8 Company Profiles-Europe 127
  134. 8.1 Actigenics SA 127
  135. 8.2 Amaxa 127
  136. 8.3 AstraZeneca PLC 128
  137. 8.4 Cenix Bioscience GmbH 128
  138. 8.5 deVGen N.V. 129
  139. 8.6 DNAVision 129
  140. 8.7 Exiqon 130
  141. 8.8 Genovis 130
  142. 8.9 genOway 130
  143. 8.10 imaGenes GmbH 131
  144. 8.11 MWG Biotech AG 131
  145. 8.12 OZ Biosciences 131
  146. 8.13 Prosensa Holding 132
  147. 8.14 QIAGEN 132
  148. 8.15 RNAx GmbH (Germany) 133
  149. 8.16 Roche 134
  150. 8.17 Rosetta Genomics, Ltd. 135
  151. 8.18 Santaris Pharma A/S 135
  152. 8.19 Silence Therapeutics PLC 136
  153. 8.20 TaconicArtemis GmbH 137
  154. 8.21 TRANSAT 137
  155. 9 Company Profiles-Asia-Pacific 139
  156. 9.1 alphaGEN Co., Ltd. 139
  157. 9.2 Benitec, Ltd. 139
  158. 9.3 Bioneer 139
  159. 9.4 CytoPathfinder, Inc. 140
  160. 9.5 Genesis Research & Development Corp. 140
  161. 9.6 GeneDesign, Inc. 141
  162. 9.7 GNI Pharmaceutical Corporation 141
  163. 9.8 Koken Co., Ltd. 141
  164. 9.9 NanoCarrier Co., Ltd. 141
  165. 9.10 Oncolys Biopharma, Inc. 142
  166. 9.11 RealGene Bio-Technologies, Inc. 142
  167. 9.12 Samchully Pharmaceuticals 142
  168. 9.13 Samyang Corp. 142
  169. 9.14 Shanghai Biochip 143
  170. 9.15 Shanghai GenePharma Co. 143
  171. 9.16 Shanghai Genomics, Inc. 143
  172. 9.17 Transgene Biotek, Ltd. 144
  173. 10 Company Profiles-Rest of the World 145
  174. 10.1 Benitec, Ltd. 145
  175. 10.2 Tekmira 146
  176. INDEX OF TABLES
  177. Table 2.1: Advantages/Disadvantages of siRNAs and shRNAs as Inducers of RNAi in Mammalian Cells 19
  178. Table 2.2: Prevalence of siRNA-mediated RNAi in Disease Models, as Reported in Scientific Literature 21
  179. Table 2.3: RNAi-based Therapeutics in Clinical Trials 22
  180. Table 2.4: Suppliers of Enabling Technologies and Tools in RNAi Space 23
  181. Table 2.5: Suppliers of siRNA/shRNA Products (by Product/Service Class) 24
  182. Table 3.1: Currently-Utilized Technologies for Inducing RNAi-Mediated Knockdown 30
  183. Table 3.2: Comparison of mRNA Detection Technologies 30
  184. Table 3.3: Strategies for Target Validation by Pharma/Biotech: RNAi and Others 31
  185. Table 3.4: Comparison of Formats for Library-Based Gene Knockdown 33
  186. Table 3.5: Characteristics of Various Publicly-Available Mouse and Human RNAi Libraries 34
  187. Table 3.6: Disease-Related miRNAs 43
  188. Table 3.7: Publicly-Available Computational Programs for Identifying miRNA Sequences/Targets 44
  189. Table 3.8: Seminal Patents in RNAi 48
  190. Table 3.9: Venture Capital Raised by Selected Companies in the RNAi Space 50
  191. Table 3.10: List of Public Biotech Companies in RNAi Space 50
  192. Table 3.11: SWOT Analysis of siRNA Oligonucleotides 52
  193. Table 3.12: Transfection Reagents (Lipid-Mediated Delivery) 53
  194. Table 3.13: shRNA Plasmid Constructs 53
  195. Table 3.14: shRNA Pooled Libraries or Arrayed Collections (Retroviral/Lentiviral Delivery) 54
  196. Table 5.1: RNAi Market Segmentation and Research Settings 74
  197. Table 5.2: Segment 1: Basic Life Science Research Utilizing RNAi Tools and Technologies 74
  198. Table 5.3: Segment 2: RNAi for Drug Discovery and Development 75
  199. Table 5.4: Segment 3: RNAi Research for Development of RNAi Therapeutics 75
  200. Table 5.5: Segment 4: RNAi Fee-for-Service Business 76
  201. Table 5.6: Grants Awarded and Research Spending in miRNA Space, 2005 to 2008 76
  202. Table 5.7: RNAi Opportunity and Market Size: Quantitative Model, 2006 to 2009 78
  203. Table 5.8: Challenges for RNAi Therapeutic Development 81
  204. Table 5.9: Technology Platforms used in RNAi Research 82
  205. Table 6.1 : Similarities Between Antisense Oligonucleotides and siRNAs 86
  206. Table 6.2: Disadvantages of siRNA Versus Antisense Oligonucleotides 86
  207. Table 6.3: Delivery Vectors for siRNA and Hairpin-Encoding DNA for In Vivo Experiments. 87
  208. Table 6.4: Delivery Systems for siRNA and Hairpin-Encoding DNA for In Vivo Experiments. 88
  209. Table 6.5: Delivery Systems for RNAi-based Therapeutics 88
  210. Table 6.6: Diseases for RNAi Therapeutics 89
  211. Table 6.7: RNAi-Based Therapeutics Pipeline-Broken Out by Disease/Therapeutic Area 90
  212. Table 6.8: RNAi-Based Therapeutics Pipeline-Broken Out by Stage of Development 90
  213. Table 6.9: Most Common Types of Cancer 91
  214. Table 6.10: RNAi Therapeutics for Cancer in Phase I 91
  215. Table 6.11: RNAi Therapeutics for Cancer in IND 92
  216. Table 6.12: RNAi Therapeutics for Cardiac Disease in IND 92
  217. Table 6.13: RNAi Therapeutics for Cardiac Disease in Pre-clinical/Research 93
  218. Table 6.14: RNAi Therapeutics for Immunologic Disease in Pre-clinical / Research 93
  219. Table 6.15: RNAi Therapeutics for Infectious Disease in Phase II 94
  220. Table 6.16: RNAi Therapeutics for Infectious Disease in Phase I 94
  221. Table 6.17: RNAi Therapeutics for Infectious Disease in IND 95
  222. Table 6.18: RNAi Therapeutics for Infectious Disease in Pre-clinical/Research 95
  223. Table 6.19: RNAi Therapeutics for Inflammatory Disease in Pre-clinical/Research 96
  224. Table 6.20: RNAi Therapeutics for Life Style Therapies in IND 96
  225. Table 6.21: RNAi Therapeutics for Metabolic Disease in Pre-clinical/Research 96
  226. Table 6.22: RNAi Therapeutics for Neurologic Disease in Pre-clinical/Research 97
  227. Table 6.23: RNAi Therapeutics for Ophthalmic Disease in Phase III 98
  228. Table 6.24: RNAi Therapeutics for Ophthalmic Disease in Phase II 98
  229. Table 6.25: RNAi Therapeutics for Ophthalmic Disease in Phase I 98
  230. Table 6.26: RNAi Therapeutics for Ophthalmic Disease in Pre-clinical/Research 98
  231. Table 6.27: RNAi Therapeutics for Renal Disease in Phase I 99
  232. Table 6.28: RNAi Therapeutics for Respiratory Disease in Pre-clinical/Research 99
  233. Table 7.1: Nucleonics Products and Programs Ongoing/Pipeline 118
  234. Table 7.2: Quark's Product Pipeline 120
  235. Table 8.1: Santaris' Product Pipeline 136
  236. Table 8.2: Silence Therapeutics' Product Pipeline 137
  237. INDEX OF FIGURES
  238. Figure 2.1: The miRNA Processing Pathway 15
  239. Figure 2.2: Growth of Scientific Publications Addressing miRNAs, 2001 to 2008 16
  240. Figure 2.3: Mechanisms of Small RNA-induced Gene Regulation 17
  241. Figure 2.4: Types of RNAi Compounds 19
  242. Figure 2.5: Breakdown of Scientific Publications Related to RNAi by Geographic Region, 2007 to 2008 20
  243. Figure 3.1: End-User Segmentation of RNAi Space 28
  244. Figure 3.2: RNAi Patents Filed Globally, by Geographical Origin 49
  245. Figure 3.3: Selected Deals in RNAi Space 51
  246. Figure 4.1: Geographical Breakdown of RNAi End-User Survey Respondents 56
  247. Figure 4.2: Affiliation of RNAi End-User Survey Respondents 56
  248. Figure 4.3: Utilization of RNAi Technologies/Products by Respondent Pool 56
  249. Figure 4.4: RNAi Utilization Period: Breakdown of Respondent Pool 57
  250. Figure 4.5: Research Applications Using RNAi Technologies/Products 58
  251. Figure 4.6: Types of RNAi Technologies Currently Utilized 59
  252. Figure 4.7: RNAi Technologies Most Commonly Utilized Currently by End-Users 59
  253. Figure 4.8: Types of RNAi Technologies: Expected Use in Six to 18 Months 60
  254. Figure 4.9: Evolution of Market Shares of RNAi-Inducing Technologies 61
  255. Figure 4.10: Number of Experiments Involving RNAi Conducted per Week 61
  256. Figure 4.11: Range of Research Dollars Spent Monthly on RNAi Research 62
  257. Figure 4.12: RNAi Experiment Throughput Correlated with Type of RNAi Technology Used 63
  258. Figure 4.13: Current RNAi Market Share by Segments 64
  259. Figure 4.14: Growth/Decline Rate of RNAi Marketplace Segments (Six to 18 Months) 65
  260. Figure 4.15: Product Formats Utilization for RNAi Research (Current and Six to 18 Months) 66
  261. Figure 4.16: Companies Offering Product Formats for Currently-Used RNAi Products 68
  262. Figure 4.17: RNAi Product Offerings/Formats Use (Projections-Six to 18 Months) 69
  263. Figure 4.18: Percentage Change of RNAi Product Offerings/Formats (Six to 18 Months) 70
  264. Figure 4.19: Key Challenges Faced by End-Users in RNAi Space 71
  265. Figure 4.20: Unmet Needs in RNAi Space Ranked by Importance to End-Users 72
  266. Figure 5.1: Growth and Evolution of miRNA Space 77
  267. Figure 5.2: Elements of RNAi Value Chain 78
  268. Figure 5.3: Growth and Evolution of RNAi (siRNA/shRNA) Space 79
  269. Figure 5.4: Market Revenues Based on Components of siRNA Experimental Paradigm 81
Registration
Browse Reports
Search TriMark
Reading Room
My Account
View Cart
Home  |  Reports  |  Database Tables  |  Conferences  |  Contact Us  
     © 2008 TriMark Publications, LLC. All rights reserved.